Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis makes Chinook Therapeutics $3.2B offer
10:23am, Monday, 12'th Jun 2023
Chinook Therapeutics, Inc stock surged by more than half in early trade after the company said it agreed to a $40 per share buyout offer by Novartis AG (ADR) (NYSE:NVS). The $3.2 billion offer repr
Chinook Therapeutics Stock Surges After Novartis Agrees $3.5 Billion Deal
06:38am, Monday, 12'th Jun 2023
Chinook said it has entered an agreement to be acquired by Novartis for $40 per share in cash, with additional cash contingent on regulatory progress with astrasentan, its kidney disease drug candidat
Chinook Therapeutics stock surges on deal to be bought for up to $3.5 billion by Novartis
05:45am, Monday, 12'th Jun 2023
Shares of Chinook Therapeutics KDNY, +0.17% rose 67% to $40.02 after it agreed to be bought by Novartis NVS, +0.28% for up to $3.5 billion. Holders of Chinook will receive $3.2 billion, or $40 per sha
Novartis agrees to buy Chinook Therapeutics for up to $3.5 billion
01:33am, Monday, 12'th Jun 2023
Novartis agreed to acquire clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments.
Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline
01:23am, Monday, 12'th Jun 2023
Novartis said on Monday it agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare sev
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
03:13pm, Friday, 09'th Jun 2023
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
5 Dividend Growth Stocks to Buy for Outperformance
09:37am, Thursday, 08'th Jun 2023
Toll Brothers (TOL), Walmart (WMT), W.W. Grainger (GWW), Novartis (NVS) and Graphic Packaging (GPK) could be compelling picks for outperformance amid market volatility.
Novartis' Sandoz to generate additional $3 bln in net sales over next five years
01:38am, Thursday, 08'th Jun 2023
Novartis' soon to be spun off generics division Sandoz is expected to expand its pipeline and generate an additional $3 billion in net sales over the next five years, the Swiss group said on Thursday.
Is Novartis a Good Stock to Buy Right Now?
03:05pm, Wednesday, 07'th Jun 2023
Novartis is moving through a long-winded transition phase right now. This process is set to culminate in the upcoming spin-off of the generic drug unit, Sandoz, later this year.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
03:56pm, Monday, 05'th Jun 2023
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Why Novartis (NVS) is a Great Dividend Stock Right Now
12:56pm, Monday, 05'th Jun 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug
12:43pm, Friday, 02'nd Jun 2023
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the latest research that finds Kisqali - a breast cancer drug made by the company - lowers the risk of recurrence by 25%.
Here's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now
11:09am, Friday, 02'nd Jun 2023
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
08:06am, Friday, 02'nd Jun 2023
Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients an
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
06:48pm, Thursday, 25'th May 2023
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of hea
